31-Oct-2016 - Lonza Group Ltd

Lonza reports strong Q3 momentum

Guidance 2018 expected to be achieved one year ahead of time

Lonza recorded another strong quarter in terms of sales and earnings. The overall company results were a consequence of continued good performance in both the Specialty Ingredients and the Pharma&Biotech segments.

“We have experienced a continuous growth pattern, which is further proof that our strict market focus is paying off. Although we are satisfied with progress, we still have a long way to go. That’s why we’ll keep emphasizing improvement projects, organic growth, portfolio management and operational excellence going forward,” said Richard Ridinger, CEO of Lonza. “Our focus remains on strengthening our position as a leading supplier to the pharmaceutical, biotech and our different specialty ingredients markets.”

Pharma&Biotech Segment

The Pharma&Biotech segment showed continued strong performance in revenue and profitability. This progress was driven by all businesses.

Commercial Manufacturing made further gains in strengthening the future of the business by extending contracts in terms of volume and timeframe. This success was further fueled by new indications and new drug applications for our customers’ products in our pipelines.

Clinical Development Services was on track, benefiting from continued strong demand for API development and clinical manufacturing services.

Bioscience Solutions maintained positive momentum in Q3. The business was further strengthened by new product introductions and the integration of Triangle Research Labs, which was acquired in June 2016.

Specialty Ingredients Segment

Lonza’s Specialty Ingredients segment continues to focus on portfolio management and higher-value activities. It delivered robust results throughout all markets with the exception of Agro Ingredients, which was negatively impacted by the overall industry downturn and pricing pressures for animal nutrition in China.

Consumer Care growth was driven by ongoing demand in all businesses. Hygiene continued to add new contracts for various technologies. The Nutrition business is expected to accelerate growth with the acquisition of InterHealth in September 2016, which will allow Lonza to harness the team’s proven management and branding capabilities and leverage them to a global level.

Coatings & Composites reported stable demand and good performance across all relevant markets driven by strong results in the Wood Protection business. The aerospace business in particular was strong, driven by success of key customer projects.

Water Treatment’s business in the third quarter was strong for the residential business and Industrial, Commercial, Municipal and Surface Water delivered a good performance overall.

Facts, background information, dossiers
  • quarterly reports
  • Lonza
More about Lonza
  • News

    Lonza Starts 2017 with Outstanding First Quarter

    During the first quarter of 2017, Lonza achieved another record quarter in terms of sales and earnings. The healthy overall company performance resulted from particularly strong performance in the Pharma&Biotech segment and continued robust growth in the Specialty Ingredients segment. “Foll ... more

    Lonza Acquires Chemical Company Zelam Based in New Zealand

    Lonza announced that it has acquired Zelam, a research-focused chemical company based in New Zealand, which develops and manufactures products for crop protection, specializing in fungicides, insecticides, herbicides, foliar nutrients and additives. Zelam also develops and manufactures prod ... more

    Lonza announces price increase for three product lines

    Lonza has announced that, due to price increases of key raw materials and tightening conditions in the marketplace, it will be implementing a 5% to 10% price increase for Hygiene and Water Treatment applications in Europe, Africa and the Middle East for the BardacTM, BarquatTM and LonzabacT ... more

  • Companies

    Lonza Ltd.

    Lonza continues to leverage its core strengths in innovation, technology, and regulatory expertise while capturing cross-divisional synergies in manufacturing, research, and sales. By clicking the Factsheet will find a detailed breakdown of our management committees, business divisions, gro ... more

    Lonza Verviers, S.p.r.l.


    Lonza Ibérica SA

    Lonza Ibérica is responsible for the sales and market development of Fine Chemicals, Biocides, Vitamines and other Exclusive products cGMP or not in Spain and Portugal. Moreover, some of our business is in the area of Custom Synthesis for Life Science companies. Lonza Ibérica works as our c ... more